VaramirStart free · no cardSign in
CRVS as of Nov 3 · 02:19 ET
CRVSNasdaqPharmaceutical Preparations

Corvus Pharmaceuticals, Inc. · Brief

Next report

Today

Nov 3 · after closeest.Q3 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
0 of 8≥ implied
avg implied
±18.2%
avg realized
±8.3%
Nov 12 '24±16.1%▲+2.07%×0.13
Mar 25 '25±25.1%▼−14.76%×0.59
May 8 '25±33.8%▲+32.24%×0.96
Aug 7 '25±12.4%▲+4.36%×0.35
Q3 FY25±20.0%▼−1.44%×0.07
Q1 FY26±11.8%▼−4.31%×0.36
May 7 '26±12.5%▲+6.58%×0.53
Q2 FY26±13.7%▲+0.43%×0.03
quarterimplied−35%0+35%realized×
Q2 FY26±13.7%▲+0.43%×0.03
May '26±12.5%▲+6.58%×0.53
Q1 FY26±11.8%▼−4.31%×0.36
Q3 FY25±20.0%▼−1.44%×0.07
Aug '25±12.4%▲+4.36%×0.35
May '25±33.8%▲+32.24%×0.96
2 older reports
Mar '25±25.1%▼−14.76%×0.59
Nov '24±16.1%▲+2.07%×0.13
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 3 report · est.

Bull2 of 4

+9.95%change in shares held by the ten largest reporting managers over the latest quarter13F · Jun 30 '26
4tracked funds holding CRVSN-PORT · Aug 31 '26

Bear2

0.41%of State Street SPDR S&P Biotech ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26
25managers whose positions together make up four fifths of the reported value13F · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

CRVS report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 20impliedImplied move: ±17.0% into Nov 3 earnings (Oct 20 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.